SCYNEXIS, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company that develops innovative antifungal therapies to treat and prevent difficult-to-treat and drug-resistant fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections, vulvovaginal candidiasis (VVC), and recurrent VVC. The company offers BREXAFEMME (ibrexafungerp) tablets as an FDA-approved oral treatment for VVC and recurrent VVC in females; its lead product candidate ibrexafungerp, a novel triterpenoid antifungal available in oral and intravenous formulations, targets invasive candidiasis/candidemia, invasive aspergillosis, and other systemic fungal diseases; and SCY-247, an oral triterpenoid antifungal in development for invasive candidiasis with Phase 2 studies planned to yield proof-of-concept data in 2026. Founded in 1999 and headquartered in Jersey City, New Jersey, SCYNEXIS operates primarily in the United States with licensing and collaboration agreements including GlaxoSmithKline (GSK), Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., and others for the development, manufacture, and commercialization of ibrexafungerp across various regions. Recent developments include a October 2025 resolution of a dispute with GSK via a new license agreement that provides SCYNEXIS with $24.8 million in one-time payments received in Q4 2025, extending its cash runway beyond two years; GSK's 2023 exclusive global license (excluding greater China and select countries) for ibrexafemme commercialization with upfront and milestone payments; and November 2025 federal funding awarded to a Hackensack Meridian CDI-Johns Hopkins collaboration utilizing SCYNEXIS's triterpenoid platform for novel antifungal compounds.
Company News
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average – Here’s What Happened
SCYNEXIS to Participate in Upcoming Investor Conferences
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200 Day Moving Average – Time to Sell?
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript